Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 10
Submit an article Journal homepage
508
Views
30
CrossRef citations to date
0
Altmetric
Letters to the Editor

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)

Elżbieta Iskierka-JażdżewskaDepartment of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland;
,
Marek HusDepartment of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland;
,
Krzysztof GiannopoulosExperimental Hematooncology Department, Medical University of Lublin & Hematology Department, St. John's Cancer Center, Lublin, Poland;
,
Elżbieta MądroDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
,
Jadwiga HołojdaDepartment of Hematology, Specialist District Hospital, Legnica, Poland;
,
Magdalena PiotrowskaDepartment of Hematology, Cracow University Hospital, Cracow, Poland;
,
Jan M. ZauchaDepartment of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland & Gdynia Oncology Center, Gdynia, Poland;
,
Weronika PiszczekDepartment of Hematology, Copernicus Hospital, Torun, Poland;
,
Agnieszka SzeremetDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland;
,
Małgorzata WojciechowskaDepartment of Hematology, Specialist District Hospital, Olsztyn, Poland;
,
Paweł SteckiewiczDepartment of Hematology, Holycross Cancer Center, Kielce, Poland;
,
Wanda Knopińska-PosłusznyDepartment of Hematology, Independent Public Health Care of the Ministry of the Internal Affairs with the Oncology Centre, Olsztyn, Poland;
,
Marek OsowieckiDepartment of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland;
,
Joanna Drozd-SokołowskaDepartment of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland;
,
Beata KumiegaDepartment of Haematooncology, Oncology Centre of the Podkarpackie Province, Brzozow, Poland;
,
Sławomira Kyrcz-KrzemieńDepartment of Hematology and Bone Marrow Transplantation, Silesian Medical University Hospital SPSKM, Katowice, Poland;
,
Janusz HałkaDepartment of Hematology, Military Institute of Medicine, Warsaw, Poland;
,
Marek DudzińskiDepartment of Hematology, Specialist District Hospital, Rzeszow, Poland;
,
Paulina WieszczyDepartment of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland
,
Tadeusz RobakDepartment of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland;
,
Krzysztof WarzochaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
&
Krzysztof JamroziakDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland; Correspondence[email protected]
 show all
Pages 2485-2488 | Received 19 Aug 2016, Accepted 03 Feb 2017, Published online: 28 Feb 2017

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Elżbieta Iskierka-Jażdżewska & Tadeusz Robak. (2020) Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. Expert Review of Hematology 13:1, pages 39-53.
Read now
Elisabeth Nuttall, Joanna Tung, Ellie Trounce, Rosalynd Johnston & Timothy Chevassut. (2019) Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis. Journal of Blood Medicine 10, pages 199-208.
Read now
Bartosz Puła, Aleksander Salomon-Perzyński, Monika Prochorec-Sobieszek & Krzysztof Jamroziak. (2019) Immunochemotherapy for Richter syndrome: current insights. ImmunoTargets and Therapy 8, pages 1-14.
Read now
Prithviraj Bose, Lisa S. Chen & Varsha Gandhi. (2019) Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the ‘real world’. Leukemia & Lymphoma 60:7, pages 1603-1605.
Read now
Phu N. Tran & Susan O’Brien. (2017) The safety of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Expert Opinion on Drug Safety 16:9, pages 1079-1088.
Read now

Articles from other publishers (25)

İbrahim Ethem PINAR & Vildan OZKOCAMAN. (2023) Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma. The European Research Journal 9:6, pages 1483-1492.
Crossref
Gianluigi Reda, Veronica Mattiello, Anna Maria Frustaci, Andrea Visentin, Francesca Romana Mauro, Idanna Innocenti, Massimo Gentile, Diana Giannarelli, Alessandro Noto, Ramona Cassin, Antonino Neri, Luca Laurenti & Alessandra Tedeschi. (2023) Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort. Blood Advances 7:4, pages 525-528.
Crossref
Andrea Urtasun, Gladys G. Olivera, Luis Sendra, Salvador F. Aliño, Pablo Berlanga, Pablo Gargallo, David Hervás, Julia Balaguer, Antonio Juan-Ribelles, María del Mar Andrés, Adela Cañete & María José Herrero. (2023) Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy. Cancers 15:5, pages 1424.
Crossref
Michael Arustamyan, Pavel Kibrik, Dilara Hatipoglu, Brandon Bungo, Amgad Mentias, Brian T. Hill & Rohit Moudgil. (2022) The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review. European Journal of Haematology 109:6, pages 696-710.
Crossref
Gabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, Anna Maria Frustaci, Riccardo Moia, Clara Deambrogi, Silvia Rasi, Francesco Autore, Michele Merli, Roberta Mattarucchi, Gaby Fahrni, Lydia Scarfo’, Daniela Gussetti, Pietro Bulian, Annagiulia Zanatta, Valeria Spina, Alessio Bruscaggin, Katia Pini, Deborah Piffaretti, Maria Cristina Pirosa, Matin Salehi, Joyce Marques de Almeida, Jakob Passweg, Franco Cavalli, Emanuele Zucca, Bernhard Gerber, Georg Stussi, Valter Gattei, Paolo Ghia, Michael Gregor, Francesco Passamonti, Luca Laurenti, Gianluca Gaidano, Alessandra Tedeschi, Davide Rossi & Adalgisa Condoluci. (2022) Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia. Hematological Oncology 40:5, pages 1100-1104.
Crossref
Sigrid S. Skånland & Geir E. Tjønnfjord. (2022) Determining drug dose in the era of targeted therapies: playing it (un)safe?. Blood Cancer Journal 12:8.
Crossref
Sarah Nocco, Tyler M. Andriano, Arpita Bose, Marina Chilov, Kendra Godwin, George Dranitsaris, Shenhong Wu, Mario E. Lacouture, Lindsay E. Roeker, Anthony R. Mato & Alina Markova. (2022) Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 174, pages 103696.
Crossref
Ai OmiFumi Nomura, Shigeharu Tsujioka, Akiko Fujino & Reiko Akizuki. (2022) Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance. Journal of Clinical and Experimental Hematopathology 62:3, pages 136-146.
Crossref
Jing-Zhou Hou, Kellie Ryan, Senxi Du, Bruno Fang, Stanley Marks, Ray Page, Eileen Peng, Keith Szymanski, Sharon Winters & Hannah Le. (2021) Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Future Oncology 17:35, pages 4959-4969.
Crossref
Pau Abrisqueta, Javier Loscertales, Maria José Terol, Ángel Ramírez Payer, Macarena Ortiz, Inmaculada Pérez, Carolina Cuellar-García, Margarita Fernández de la Mata, Alicia Rodríguez, Ana Lario, Julio Delgado, Ana Godoy, José Mª Arguiñano Pérez, Mª José Berruezo, Ana Oliveira, José-Ángel Hernández-Rivas, Maria Dolores García Malo, Ángeles Medina, Paloma García Martin, Santiago Osorio, Patricia Baltasar, Miguel Fernández-Zarzoso, Fernando Marco, Mª Jesús Vidal Manceñido, Alicia Smucler Simonovich, Montserrat López Rubio, Isidro Jarque, Alexia Suarez, Rubén Fernández Álvarez, Aima Lancharro Anchel, Eduardo Ríos, María del Carmen Losada Castillo, Ernesto Pérez Persona, Ricardo García Muñoz, Rafael Ramos, Lucrecia Yáñez, José Luis Bello, Cristina Loriente, Daniel Acha & Miguel Villanueva. (2021) Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Clinical Lymphoma Myeloma and Leukemia 21:12, pages e985-e999.
Crossref
Stefanie L. Groenland, Mark J. Ratain, Lisa S. Chen & Varsha Gandhi. (2021) The Right Dose: From Phase I to Clinical Practice. American Society of Clinical Oncology Educational Book:41, pages 92-106.
Crossref
Marcin M. Machnicki, Patryk Górniak, Monika Pępek, Agnieszka Szymczyk, Elżbieta Iskierka‐Jażdżewska, Paweł Steckiewicz, Aleksandra Bluszcz, Małgorzata Rydzanicz, Marek Hus, Rafał Płoski, Hanna Makuch‐Łasica, Grażyna Nowak, Przemysław Juszczyński, Krzysztof Jamroziak, Tomasz Stokłosa & Bartosz Puła. (2020) Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. European Journal of Haematology 106:3, pages 320-326.
Crossref
Sigrid S. Skånland & Anthony R. Mato. (2021) Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Advances 5:1, pages 334-343.
Crossref
Camille Hardy-Abeloos, Rachel Pinotti & Janice Gabrilove. (2020) Ibrutinib dose modifications in the management of CLL. Journal of Hematology & Oncology 13:1.
Crossref
Paul J. Hampel, Timothy G. Call, Kari G. Rabe, Wei Ding, Eli Muchtar, Saad S. Kenderian, Yucai Wang, Jose F. Leis, Thomas E. Witzig, Amber B. Koehler, Amie L. Fonder, Susan M. Schwager, Daniel L. Van Dyke, Esteban Braggio, Susan L. Slager, Neil E. Kay & Sameer A. Parikh. (2020) Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. The Oncologist 25:11, pages 974-980.
Crossref
Abraham M. Varghese, Nitin Sood & Sunitha M. Daniel. (2020) Current pricing model for cancer drugs ‒ is it ‘Justum Pretium’ for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration. British Journal of Haematology 190:5.
Crossref
Bartosz Puła, Aleksandra Gołos, Patryk Górniak & Krzysztof Jamroziak. (2019) Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. Cancers 11:12, pages 1834.
Crossref
Yanhua Zhou, Hongtao LuMeifeng Yang & Chenhong Xu. (2019) Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia. Medicine 98:33, pages e16915.
Crossref
Inhye E. AhnNeil Basumallik, Xin Tian, Susan SotoAdrian Wiestner. (2019) Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood 133:22, pages 2452-2455.
Crossref
Peter Georgantopoulos, Huiying Yang, LeAnn B. Norris & Charles L. Bennett. (2019) Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors. Cancer Medicine 8:5, pages 2233-2240.
Crossref
Carol Moreno, Carolina Cuellar & Eva Puy Vicente. 2019. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 123 136 .
Lisa S. ChenPrithviraj BoseNichole D. CruzYongying JiangQi WuPhilip A. ThompsonShuju Feng, Michael H. Kroll, Wei Qiao, Xuelin Huang, Nitin JainWilliam G. WierdaMichael J. KeatingVarsha Gandhi. (2018) A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132:21, pages 2249-2259.
Crossref
Anna Maria Frustaci, Alessandra Tedeschi, Marina Deodato, Maddalena Mazzucchelli, Roberto Cairoli & Marco Montillo. (2018) Ibrutinib and its use in the treatment of chronic lymphocytic leukemia. Future Oncology 14:8, pages 681-697.
Crossref
Benjamin F. Tillman, James M. Pauff, Gowri Satyanarayana, Mahsa Talbott & Jeremy L. Warner. (2018) Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. European Journal of Haematology 100:4, pages 325-334.
Crossref
Krzysztof Jamroziak, Agnieszka Szymczyk, Marek Hus, Małgorzata Wojciechowska, Wanda Knopinska‐Posłuszny, Jadwiga Hołojda, Kazimierz Hałaburda, Krzysztof Warzocha & Elżbieta Iskierka‐Jażdżewska. (2018) Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report ( PALG ) . European Journal of Haematology 100:4, pages 389-391.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.